Sun Pharmaceutical Industries Ltd is the world’s fourth-largest specialty generic pharmaceutical company. With a network of over 40 manufacturing facilities, the company distributes medicines to more than over 100 countries worldwide. The company has a global employee base of over 41,000.
The company’s recent acquisition of Concert Pharmaceuticals Inc in the United States has granted it access to the late-stage asset deuruxolitinib, which has completed Phase-3 studies for treating alopecia areata.
Founded in 1983, Sun Pharma has a market capitalisation of ₹2,98,705 crore as of December 19, 2023. Sun Pharma share price has gained 114% in the last 3 years.
Business portfolio
The company manufactures and markets a wide range of pharmaceutical formulations, which include generics, branded generics, over-the-counter, antiretrovirals, intermediates and active pharmaceutical ingredients.
In specialty medications, Sun Pharma has a portfolio of patent-protected drugs. With focus on dermatology, ophthalmology and oncology, the company aims to improve patient outcomes by addressing unmet medical needs and enhancing convenience through diverse dosage forms.
Sun Pharma provides high-quality generic and branded medicines to patients and healthcare professionals in over 100 countries. These medicines are available in tablets, capsules, injectables, inhalers, ointments, creams and liquids.
The therapeutic segments covered by the company’s portfolio includes psychiatry, anti-infectives, neurology, cardiology, orthopaedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Sun Pharma consistently ranks among the leading companies in these therapy areas.
Presently, it’s one of the top companies in the United States, having introduced a number of speciality items.
When it comes to over-the-counter medications, Sun Pharma’s range is diverse. Its flagship OTC brands such as Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics) are available globally.
With regards to active pharmaceutical ingredients (APIs), Sun Pharma began producing them in 1995. The company manufactures more than 300 APIs that are sold in over 60 countries. These are manufactured in 14 sites spread across India, Hungary, the United States, Israel and Australia.
Sun Pharma provides a selection of antiretroviral (ARV) drugs that have been prequalified by the WHO. The company works with groups like the Clinton Health Access Initiative (CHAI) to lower the cost of triple medication combinations and provides ARVs to various National AIDS treatment programmes in Africa.
Bioequivalent ARV medications and APIs are produced at WHO-prequalified facilities in India, a PIC/S-approved facility in South Africa and a plant in Russia, all of which are part of Sun Pharma’s portfolio.
Sun Pharmaceutical Industries Financial Highlights
- Revenue: Sun Pharmaceutical Industries reported revenue of ₹60,433.76 crore in FY26 vs ₹54,543.48 crore in FY25. It showed an increase of 10.80% on a yearly basis.
- Operating Profit: Sun Pharmaceutical Industries reported an operating profit of ₹15,118.88 crore in FY26 vs ₹13,752.13 crore in FY25. It showed an increase of 9.94% on a year-on-year basis.
- Net Profit: Sun Pharmaceutical Industries reported a net profit of ₹11,564.52 crore in FY26 vs ₹10,980.10 crore in FY25. It showed an increase of 5.32% on a yearly basis.
Sun Pharmaceutical Industries Quarterly Result Highlights
- Sun Pharmaceutical Industries reported revenue of ₹15,070.29 crore in Mar 2026, compared with ₹16,099.38 crore in Dec 2025, representing a decrease of 6.39% on a quarter-on-quarter (QoQ) basis.
- Sun Pharmaceutical Industries reported an operating profit of ₹3,551.34 crore in Mar 2026, compared with ₹4,227.16 crore in Dec 2025, representing a decrease of 15.99% on a quarter-on-quarter (QoQ) basis.
- Sun Pharmaceutical Industries reported a profit of ₹2,723.72 crore in Mar 2026, compared with ₹3,401.09 crore in Dec 2025, reflecting a decrease of 19.92% on a QoQ basis.
- The earnings per share (EPS) of Sun Pharmaceutical Industries stood at ₹47.80 during Mar 2026.
